Should I Pursue Emerging Medtech Markets?
Global healthcare spending is roughly $7 trillion, according to Matthew Hein, International Trade Specialist for the U.S. Department of Commerce. Considering the market outside of the United States is about 25% larger, companies may have more success pursuing product approval in emerging markets—beyond China, India and Brazil—because the technologies may be more helpful for those patient populations and the regulatory burdens more manageable, suggests Hein in the following video, which was filmed during the MedTech Intelligence Global Regulatory conference last week.
Related Articles
-
Market research and forecasting help ensure that you are investing in a device or drug that is needed and will be well received. In this article, Sanobar Syed, Associate Director of Forecasting, Market Insights and Strategies, BeiGene, highlights strategies to…
-
As VP of Product Marketing for a MedTech startup, my role is to champion pioneering medical technology, strategically spark interest and drive it out of the design lab and into the field where it will ultimately change, or even save…
-
Veeva Vault CRM for Medtech is a unified customer relationship management (CRM) and content management application built for medtech sales teams, key account managers and medical affairs professionals.
-
Medtronic will invest up to $75 million and immediately begin co-promotion of CathWorks’ FFRangio System for the noninvasive diagnosis of CAD in the U.S., Europe and Japan, where it is commercially available.
